Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Cytometry Part B: Clinical Cytometry Year : 2021

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group

Anna Porwit
Alan Dunlop
  • Function : Author
Nicolas Chapuis
Michaela Fontenay
Ulrika Johansson
Alberto Orfao
Dolores Subirá

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Domains

Cancer
Fichier principal
Vignette du fichier
Cytometry Part B Clinical - 2021 - Loosdrecht - Clinical application of flow cytometry in patients with unexplained.pdf (1.23 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03540442 , version 1 (24-01-2022)

Identifiers

Cite

Arjan Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, et al.. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group. Cytometry Part B: Clinical Cytometry, 2021, Online ahead of print. ⟨10.1002/cyto.b.22044⟩. ⟨inserm-03540442⟩
25 View
113 Download

Altmetric

Share

Gmail Facebook X LinkedIn More